Uniqure N.V. current report, 21 November 2022

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by uniQure N.V. on November 21, 2022. The filing addresses the termination of a material definitive agreement with Bristol-Myers Squibb (BMS).

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It references a potential contingent payment obligation of $70.0 million under specific change of control scenarios, but no payment is currently due.

Material Changes

  • Termination of Collaboration: BMS notified uniQure on November 21, 2022, that the amended Collaboration and License Agreement (BMS CLA) will terminate effective February 21, 2023.
  • Agreement History: The original agreement was signed in May 2015 and amended in December 2020. During the amendment period, BMS did not replace any of the four active Collaboration Targets.
  • Remaining Obligations: The Investor Agreement dated April 2015 between the Company and BMS remains in force.

Outlook, Risks, and Contingencies

  • Change of Control Contingency: The amended BMS CLA stipulates that if a change of control transaction occurs prior to December 1, 2026, or before BMS delivers a target cessation notice for all targets, uniQure (or its acquirer) must pay BMS a one-time cash payment.
  • Payment Terms: The payment is capped at $70.0 million, subject to a floor of 1% and a ceiling of 5% of the net proceeds from the change of control transaction.
  • Current Status: As of the filing date, no change of control transaction has been consummated that would trigger this payment obligation.

Investor Verification Checklist

  • Confirm the effective termination date of the BMS CLA is February 21, 2023.
  • Verify that the April 2015 Investor Agreement remains active and review its terms.
  • Monitor for any potential change of control transactions that could trigger the $70.0 million contingent payment.
  • Review the Company's Form 10-K filed on February 25, 2022, for historical financial context regarding the BMS collaboration.